Countries all over the world are recognizing the importance of biotechnology to their economies, the health and well-being of their citizens, their food supply and their ability to generate clean energy. Nearly every major country has adopted programs to generate a homegrown biotechnology sector and the well-paying jobs it supports. China is no exception.
China has included biotechnology as one of seven strategic priorities for scientific and technological development in its 12th Five-Year Plan and because of this, China is set to become the second largest pharmaceutical market in the world by 2015.
According to Gang Wan, Head of Ministry of Science and Technology, “By 2020, the total output value of China’s biological industry will reach more than 4 percent of GDP.” Furthermore, according to IMSHealth, “At $50 billion, China is the world’s number two pharma market, but is forecast to rise to $100 billion by 2015, and to become the #1 market by 2020.”
With the government’s support of growing the industry, executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia are increasingly looking to explore potential collaborations and business opportunities within China’s emerging biotech sector.
The third annual BIO Convention in China will be held November 11 – 13 at the China National Convention Center (CNCC) in Beijing, China. The conference will include plenary sessions, workshops and business roundtables, company presentations, exhibitions, and business development meetings using the BIO One-on-One PartneringTM system.
Through BIO’s One-on-One Partnering™ system, event attendees are afforded the opportunity to connect with potential partners of their choice and hold 30-minute meetings in private rooms provided by BIO onsite at the conference. BIO’s industry-specific, web-based interactive software enables participants to prepare prior to the conference by using search criteria to identify potential partners, reviewing profiles of those attending companies and sending select companies personalized meeting requests.
In addition to the partnering opportunities, attendees will hear from industry thought-leaders participating in the program sessions. Plenary sessions will be policy, scientific and business focused. Preliminary session topics include:
- China’s Private Health Care Industry
- Building a World-Class Innovative Therapeutic Biologics Industry in China
- China’s New Party Leadership, Implications for Central Planning and Regulation
- Looking Forward: 13th Five-Year Plan & Its Investment in Innovation
- Cancer Epigenetics and Emerging Therapies
- Treating NSCLC in China
- Traditional Chinese Medicine
- Diabetes Dx and Treatment in China
- Respiratory Disease in China—Treatment and Prevention
- Rare Diseases in China
- New VC Models in China
- State of Capital Markets in China
- Opportunities from EDL expansion
To learn more about the 2013 BIO Convention in China, please visit here.